FHIR/HL7 interoperability and privacy-aware healthcare analytics that unlock value while preserving clinical integrity and patient trust.
Healthcare data is uniquely sensitive and uniquely fragmented, governed by strict privacy requirements and standards like FHIR. Analytics and research stall on interoperability and privacy at the same time.
FHIR-based interoperability unlocks analytics and research while preserving privacy controls and clinical data integrity - so organizations can improve services without compromising trust.
The deeper issue is that healthcare has accumulated its systems over decades, each optimised for a specific function and never designed to share. The result is not one gap but many: a patient record fragmented across departments, an analyst unable to assemble a complete view, and a research team blocked by data that cannot be combined. Every new need has historically meant another custom interface, and each of those interfaces becomes something to maintain and something that can break.
That accumulation is expensive in ways that rarely appear as a line item. Clinicians work with partial information, integration teams spend their time keeping brittle links alive rather than enabling new capability, and the organisation cannot answer questions its own data contains. The cost is measured in effort, in missed insight, and ultimately in the quality of decisions made without a complete picture.
Compounding all of this, healthcare data is among the most sensitive an organisation holds, so the fragmentation cannot be solved by simply copying data everywhere. Any move toward interoperability has to carry privacy, consent and quality with it, which is precisely why the piecemeal, interface-by-interface approach so often stalls: it moves data without governing it, and in this domain ungoverned movement is not an option.
Healthcare has more data than ever and less ability to use it than it should, because that data sits in systems that were never designed to talk to each other. Point-to-point interfaces have accumulated into a brittle web that consumes effort and still leaves clinicians and analysts without a complete picture.
Standards-based interoperability on FHIR changes that, but only when it is designed in with governance, quality and consent rather than bolted on. The organisations that get ahead treat health data as a governed, interoperable foundation, which is exactly what this practice delivers.
For a business sponsor, the practical consequence is that the organisation's ability to use its own data, for care, for operations and for research, is gated by interoperability it has historically under-invested in. Building a governed, standards-based foundation is what unlocks that latent value, turning data the organisation already holds into insight it can finally act on.
Our point of view on healthcare data is that interoperability has to be designed in, not bolted on. Point-to-point interfaces multiply and break, consuming effort while never making the estate genuinely connected, and no amount of additional interfaces escapes that treadmill. A standards-based FHIR foundation replaces the fragility with dependable, reusable connectivity.
We also argue that interoperable is not the same as usable. Health data that is standardised but not governed for quality, privacy and consent is not safe to rely on, and in this domain data that is untrustworthy or inappropriately used is worse than no data at all. Governance is therefore inseparable from interoperability, not a later add-on.
Finally, we treat analytics as the point of the exercise rather than a downstream afterthought. Connecting systems is the means; the end is governed, interoperable data that enables clinical, operational and research analytics which siloed data makes impractical. Designing for that outcome from the start is what turns an integration project into a genuine capability.
We design so interoperability and privacy reinforce each other rather than trade off, integrating data across systems and building the governance clinical and regulatory stakeholders expect.
Our approach is to make interoperability a designed property of the estate rather than a series of one-off fixes. We standardise on FHIR so that exchange is based on a widely adopted standard, model health data to a common structure so it can be reused across clinical, operational and research needs, and build the governance, quality and consent handling that make the data safe to rely on.
We deliver this incrementally, starting with a priority set of systems or a specific use case, so the standards-based approach and the governance around it are proven before the foundation is extended. The point is not a big-bang integration programme but a durable, reusable foundation that grows, replacing the treadmill of custom interfaces with connectivity the organisation can build on.
We also treat the human and organisational side as part of the work, not an afterthought. Interoperability changes how clinical, data and technology teams collaborate, so we bring them along, transferring the FHIR modelling and governance knowledge as we go, so the foundation is understood and owned internally rather than being a black box only we can maintain.
Healthcare data is famously siloed, and interoperability is often bolted on rather than designed in. We use a five-stage model to show sponsors how far the organisation has moved toward governed, standards-based health data on FHIR, so clinical and analytical use cases rest on interoperable, trustworthy foundations.
Most organisations sit at Siloed or Interfaced, held together by brittle point-to-point links. Moving to standards-based, governed FHIR data is what turns interoperability from a constant integration burden into a dependable foundation.
Where the business is Systems do not talk to each other. Health data sits in separate silos, and clinicians and analysts lack a complete picture. For a sponsor, the practical signal is how much manual effort and disagreement surrounds the work at this point, and how much of it depends on a few individuals rather than a repeatable capability.
What it costs The cost is effort and blind spots: data that exists but cannot be used together when it matters most. Left unaddressed, this is the kind of cost that does not appear as a line item but shows up as slower decisions, avoidable rework and risk that is only priced once it materialises.
What we do We map the systems, standards and privacy requirements and design a standards-based interoperability strategy on FHIR. We do this in a contained, evidenced way, with an agreed output, so the move to the next stage is something the business can see and fund with confidence rather than take on trust.
What good looks like In practice, a sponsor can recognise this stage by the amount of manual effort and disagreement around the numbers; the goal of the first move is to make that pain visible and bounded rather than pervasive.
Where the business is Point-to-point links connect some systems, but they are brittle and multiply, consuming effort and breaking as things change. For a sponsor, the practical signal is how much manual effort and disagreement surrounds the work at this point, and how much of it depends on a few individuals rather than a repeatable capability.
What it costs Interfacing is a treadmill: each new connection adds fragility, and the estate never becomes genuinely interoperable. Left unaddressed, this is the kind of cost that does not appear as a line item but shows up as slower decisions, avoidable rework and risk that is only priced once it materialises.
What we do We model health data to FHIR so consumers share a common structure, replacing brittle links with dependable exchange. We do this in a contained, evidenced way, with an agreed output, so the move to the next stage is something the business can see and fund with confidence rather than take on trust.
What good looks like The tell-tale sign of this stage is that things look better on the surface while the underlying capability is still thin; our work here is about turning apparent order into real, evidenced control.
Where the business is Exchange is standards-based on FHIR. Data moves on a common structure rather than a web of bespoke interfaces. For a sponsor, the practical signal is how much manual effort and disagreement surrounds the work at this point, and how much of it depends on a few individuals rather than a repeatable capability.
What it costs The gap now is trust and appropriateness: standardized data still needs quality, privacy and consent to be safely used. Left unaddressed, this is the kind of cost that does not appear as a line item but shows up as slower decisions, avoidable rework and risk that is only priced once it materialises.
What we do We add data quality, privacy and consent handling so the interoperable data is also trustworthy and used appropriately. We do this in a contained, evidenced way, with an agreed output, so the move to the next stage is something the business can see and fund with confidence rather than take on trust.
What good looks like At this stage the organisation has earned genuine trust in its foundation, and the conversation shifts from fixing problems to unlocking speed, efficiency and readiness for what comes next.
Where the business is Quality and consent are in place. Interoperable health data is trustworthy and handled appropriately across uses. For a sponsor, the practical signal is how much manual effort and disagreement surrounds the work at this point, and how much of it depends on a few individuals rather than a repeatable capability.
What it costs Firms that stop here have a sound foundation but may not yet have turned it into clinical and research value. Left unaddressed, this is the kind of cost that does not appear as a line item but shows up as slower decisions, avoidable rework and risk that is only priced once it materialises.
What we do We prepare the governed, interoperable data for clinical, operational and research analytics. We do this in a contained, evidenced way, with an agreed output, so the move to the next stage is something the business can see and fund with confidence rather than take on trust.
What good looks like Reaching this stage changes how the business feels day to day: decisions rest on current information, surprises are rarer, and effort moves from keeping the lights on to creating advantage.
Where the business is Data flows where it is needed, governed and standards-based, enabling analytics and research that silos had made impractical. For a sponsor, the practical signal is how much manual effort and disagreement surrounds the work at this point, and how much of it depends on a few individuals rather than a repeatable capability.
What it costs This is where interoperability stops being a project and becomes a dependable foundation the whole organisation draws on. Left unaddressed, this is the kind of cost that does not appear as a line item but shows up as slower decisions, avoidable rework and risk that is only priced once it materialises.
What we do We help the capability extend across systems and use cases so interoperable, governed data becomes simply how the organisation works. We do this in a contained, evidenced way, with an agreed output, so the move to the next stage is something the business can see and fund with confidence rather than take on trust.
What good looks like This final stage is less a destination than a standing capability; the work here is to keep it current as conditions, regulation and the estate evolve, so the gains hold rather than decay.
Our work is built on a family of named, reusable methodologies we have developed across data, AI, cloud, governance and trading engagements. Each is a structured asset a client can recognise, reuse in its own proposals and board papers, and return to as the programme matures. The full family is below, with the assets most relevant to this practice highlighted.
Our reference operating model for running data as an enterprise capability: the bands, roles and controls that connect strategy to delivery to foundation.
A structured path from AI used-but-ungoverned to board-level assurance, mapped to the EU AI Act, NIST AI RMF and ISO 42001 and 23894.
The five-stage model we use to move a trading business from fragmented spreadsheets to a governed, real-time, intelligent capability.
A vendor-neutral target-state architecture for a governed, cost-controlled, AI-ready data platform, from sources through to consumption.
A capability index and heatmap for scoring where an organisation stands across data, AI, cloud and control, and where to invest next.
A horizon-based roadmap format that sequences change into fundable, reversible slices tied to business outcomes.
An executive heatmap of where organisations typically stand at the outset, scoring coverage across the capabilities that matter so investment can target the gaps.
Map systems, standards, and privacy requirements.
FHIR-based interoperability and privacy-aware analytics.
Connect systems; build governed data foundation.
Analytics and research within privacy controls.
Our delivery path is deliberately staged so a sponsor always knows what is being done, why, and what it produces. Each phase has a clear purpose and a tangible output, and value is proven before scope widens. The phases below are how a typical engagement unfolds.
Assess. Map systems, standards, and privacy requirements. This phase is scoped and time-boxed, with an agreed output, so it moves the engagement forward on evidence rather than open-ended effort.
Design. FHIR-based interoperability and privacy-aware analytics. This phase is scoped and time-boxed, with an agreed output, so it moves the engagement forward on evidence rather than open-ended effort.
Integrate. Connect systems; build governed data foundation. This phase is scoped and time-boxed, with an agreed output, so it moves the engagement forward on evidence rather than open-ended effort.
Enable. Analytics and research within privacy controls. This phase is scoped and time-boxed, with an agreed output, so it moves the engagement forward on evidence rather than open-ended effort.
How the capability runs end to end, from strategy and accountability at the top through governance and delivery to the cloud, data and security foundation.
We design interoperability in rather than bolting it on, standardising on FHIR so exchange is dependable and reusable rather than a growing web of brittle interfaces.
We govern quality, privacy and consent from the start, because health data is sensitive and consequential and must be both trustworthy and appropriately used.
We model for reuse, so governed, interoperable data serves clinical, operational and research needs at once rather than a new integration for every use case.
We group healthcare data work into five themes leadership can weigh, each tied to interoperable, trustworthy health data rather than a technical integration list.
A standards-based strategy on FHIR that replaces brittle point-to-point links with dependable, reusable exchange. Done well, this means dependable, standards-based interoperability with data that is trustworthy and appropriately used.
Modelling health data to FHIR so clinical and analytical consumers share a common, interoperable structure. Done well, this means dependable, standards-based interoperability with data that is trustworthy and appropriately used.
Pipelines that move and transform health data reliably between systems and into analytics. Done well, this means dependable, standards-based interoperability with data that is trustworthy and appropriately used.
Data quality, privacy and consent handling so health data is trustworthy and used appropriately. Done well, this means dependable, standards-based interoperability with data that is trustworthy and appropriately used.
Preparing governed, interoperable data for clinical, operational and research analytics. Done well, this means dependable, standards-based interoperability with data that is trustworthy and appropriately used.
Interoperability strategy sets the direction. We design a standards-based strategy on FHIR that replaces brittle point-to-point links with dependable, reusable exchange, so interoperability stops being a growing web of fragile interfaces. This is the decision that determines whether the estate becomes genuinely connected.
We standardise on FHIR precisely to escape the treadmill of point-to-point interfaces, so connectivity becomes reusable infrastructure rather than a growing maintenance burden.
On the maturity model, this theme is what carries an organisation from Siloed and Interfaced toward Standardized, because a clear strategy is the difference between escaping the interface treadmill and adding to it.
FHIR data modelling gives everyone a common structure. We model health data to FHIR so clinical and analytical consumers share the same interoperable form, rather than a new integration for every pairing. This is what makes data reusable across uses.
We model to a common structure so the same data serves clinical, operational and research needs, rather than requiring a fresh integration for every new consumer.
This is the theme that most directly enables the move to Governed and Interoperable, since a shared FHIR structure is what lets every later consumer connect once rather than through a fresh integration each time.
Pipelines and integration move data reliably. We build pipelines that transform and move health data dependably between systems and into analytics, so the foundation is operational rather than theoretical. This is where the strategy becomes working plumbing.
We build pipelines that are dependable and monitored, so interoperability is operational reality rather than an architecture diagram.
Reliable pipelines are what make the maturity model real rather than aspirational, turning a target architecture into data that actually moves dependably between systems and into analytics.
Governance, quality and consent make the data safe to use. We add quality, privacy and consent handling, so interoperable health data is trustworthy and used appropriately, which is non-negotiable in this domain. This is what lets the data be both connected and responsible.
We govern quality, privacy and consent as first-class concerns, because in healthcare data that is not trustworthy or appropriately used is worse than no data at all.
Governance is the theme that separates merely Standardized data from truly Interoperable, trustworthy data, and it is where healthcare engagements earn or lose their credibility.
Analytics enablement is where the value is realised. We prepare governed, interoperable data for clinical, operational and research analytics, so the connected foundation actually improves care and insight. This is the point of the whole effort.
We prepare the governed, interoperable foundation specifically for analytics, so the connectivity translates into better care and insight rather than stopping at integration.
Analytics enablement is where the whole climb pays off, converting a governed, interoperable foundation into the clinical, operational and research insight that justified the investment.
A capability map grouping the work into the domains a sponsor can reason about, each expandable into detailed workstreams.
A vendor-neutral target-state architecture, from sources at the base through ingestion and platform to the consumers at the top, with data and control flowing upward.
The first change is dependability: standards-based FHIR exchange replaces brittle point-to-point links, so interoperability stops being a constant integration burden.
The second is trust: governed quality, privacy and consent mean health data is both reliable and used appropriately, which is non-negotiable in this domain.
The third is capability: governed, interoperable data enables clinical, operational and research analytics that siloed, inconsistent data had made impractical.
Together, these shifts turn health data from a fragmented liability into a governed, interoperable foundation that supports better care, smoother operations and credible research.
For clinical and research leaders specifically, the change is that questions which were previously impractical, because the data sat in incompatible silos, become answerable on a governed, interoperable foundation. That shift from data the organisation holds but cannot use, to data it can act on, is where the investment ultimately proves itself.
Anonymized, representative outcomes. Actual results depend on scope, data quality and starting maturity.
Challenge Brittle point-to-point interfaces held the estate together and consumed effort.
Approach We adopted a standards-based FHIR foundation with governed quality and consent.
Outcome Interoperability became dependable, and clinical and analytical teams drew on a common, trustworthy structure.
Challenge Data from many sources needed to be combined reliably.
Approach We modelled it to FHIR and built dependable pipelines.
Outcome Fragmented feeds became governed, interoperable data ready for analytics.
Challenge Siloed, inconsistent data made research analytics impractical.
Approach We prepared governed, consent-aware health data on FHIR.
Outcome Analytics and research that had been impractical became feasible.
The sponsor's return is reduced integration burden and unlocked value. Standards-based FHIR exchange replaces the growing cost of brittle point-to-point interfaces with dependable, reusable connectivity, freeing effort that maintenance would otherwise consume.
The larger return is capability: governed, interoperable data enables clinical, operational and research analytics that siloed data makes impractical, which is where better care and insight come from. We design interoperability in from the start, so the foundation lasts rather than needing to be rebuilt.
A simple decision aid for the choice this practice most often turns on, so leadership can see the recommended path for their situation.
Why healthcare interoperability must be designed in, not bolted on.
Point-to-point interfaces multiply and break. A standards-based FHIR foundation is what makes interoperability dependable and reusable rather than a perpetual project. In our experience this is the decision sponsors most often wish they had made earlier, because getting it wrong is expensive to unwind.
Health data is sensitive and consequential. Quality, privacy and consent handling are what make it both trustworthy and appropriate to use. Treating it as a first-class principle rather than an afterthought is what separates programmes that hold up from those that quietly unravel.
Data modelled to a common standard serves clinical, operational and research needs at once, instead of a new integration for every use case. It is a small discipline that compounds, protecting both the budget and the credibility of the whole effort.
Interoperable, governed data is the precondition for clinical and research analytics. Treat it as the foundation, not a downstream afterthought. Boards that insist on this find the rest of the programme easier to govern and far easier to defend.
Interoperability retrofitted onto siloed systems stays fragile. Building on standards from the start is what makes it last. It is the difference between a capability that lasts and one that looks impressive at launch and decays soon after.
The failure modes we see most often in this work, and design engagements specifically to prevent.
Most firms can claim expertise in one or two of these areas. Our differentiator is the intersection: we bring enterprise data architecture, governance, AI, cloud, deep regulated-industry knowledge and practitioner-grade ETRM expertise together as a single integrated capability, rather than handing a problem between separate specialists who never meet. That combination is uncommon, and it is why the pieces of an engagement are designed to fit.
Healthcare interoperability sits at the intersection of data architecture, governance, cloud, the regulatory and consent context of health data, and analytics enablement. Standardising data without governing it is unsafe; governing without the architecture is theoretical. Because we hold these together, interoperable health data is also trustworthy and genuinely usable.
For the sponsor, that means one partner accountable for a governed, interoperable foundation that supports better care, smoother operations and credible research, rather than a health IT vendor selling a platform or a generalist learning the domain.
Health IT vendors sell a platform; large firms bring generalists learning the domain; internal teams are consumed by keeping interfaces alive. We bring data engineers who build governed, standards-based health data, and three things that requires.
We build governed data foundations and pipelines, so healthcare interoperability rests on real engineering and FHIR modelling, not a strategy deck. That means fewer surprises at the hard moments, because the people advising you have lived through them, and a design that reflects operational reality rather than an idealised diagram.
We are not selling a health IT platform. We build interoperable, standards-based data on tooling that fits your estate and integrate with the systems you keep. It also means you can trust the recommendation itself, because it carries no hidden incentive, and you keep the leverage that comes from not being tied to one vendor's roadmap.
FHIR modelling, data governance and analytics enablement sit together, so interoperable data is also trustworthy and genuinely usable. Because these disciplines sit in one team rather than being handed between separate specialists, the pieces are designed to fit, and you deal with one accountable partner rather than a committee of vendors.
This work serves providers, payers, health systems and research institutions, wherever fragmented health data must become interoperable and trustworthy. The interoperability maturity model applies across them.
Standards adoption, privacy regimes and consent requirements differ by jurisdiction and organisation, so we tailor governance and modelling accordingly, while the path from siloed to interoperable stays constant.
Sponsors rightly worry about the ways engagements like this go wrong, so we manage the common risks explicitly rather than leaving them to chance. Scope creep is contained by delivering in fixed, valuable slices with agreed success measures, so the programme cannot quietly expand without a decision. Delivery risk is reduced by proving value early on a contained scope before widening, so problems surface while they are small and reversible.
Key-person and knowledge risk is addressed by working alongside your teams and leaving documented, operable artifacts, so the capability does not walk out of the door when we do. Vendor and lock-in risk is managed by staying neutral and designing for the platforms that fit your constraints, so you keep leverage. And the risk of governance or controls decaying after go-live is handled by building them into daily work and, where useful, continuing in a co-managed role so the gains hold.
In healthcare specifically, we manage the additional risks around privacy, consent and clinical continuity with particular care. Data is only moved and used within the consent and classification rules that apply, the interoperability layer is proven on a contained scope before it touches anything clinicians depend on, and quality controls ensure that connecting systems improves the completeness of information rather than propagating errors between them. The result is a foundation that is both more connected and more trustworthy than what it replaces.
How we sequence the change into fundable, reversible horizons, each delivering value before the next is committed.
Engagements typically begin with a focused discovery and blueprint, a short, fixed-scope phase that baselines the current state, agrees the target and the success measures, and produces a prioritised roadmap a sponsor can fund with confidence.
From there we deliver in thin, end-to-end slices rather than a single monolithic programme, proving value early on a contained scope before widening. This keeps risk visible and reversible and gives leadership real results to point to at each step.
We work alongside your teams throughout rather than in a separate room, so knowledge transfers as we go and the capability we build is one your people can own and extend. Where it helps, we can continue in a co-managed or managed role after the initial build so the gains hold.
In every case, the shape of the engagement is designed around your funding and governance rhythm, so a sponsor can approve a contained, well-defined phase, see a tangible result, and decide on the next step with evidence in hand. This is what keeps the work accountable to the business throughout, rather than asking for faith in a long programme whose value only appears at the end.
A typical engagement moves through a small number of clearly funded steps, each of which leaves the organisation measurably more connected. We begin by mapping the systems, standards and privacy requirements and agreeing a standards-based interoperability strategy, so the sponsor knows precisely which systems and use cases the first phase will address.
From there we model health data to FHIR, build the pipelines that move it dependably, and add the governance, quality and consent handling that make it safe to rely on. Each step is a contained, evidenced slice, so clinical and analytical teams see a real result, whether that is a connected system or a governed dataset, before the next slice is funded.
The effect over the engagement is a steady climb from a siloed, interface-bound estate to a governed, interoperable foundation that analytics and research can build on. Because the work starts small and proves the standards-based approach before extending, the organisation escapes the interface treadmill without a disruptive big-bang programme, and unlocks value from data it already holds.
Throughout, we work alongside your clinical, data and technology teams rather than in isolation, so the FHIR modelling, pipelines and governance are understood and owned internally. By the end of the engagement the interoperable foundation is genuinely yours to run and extend, with the quality and consent controls that keep it trustworthy as new systems and use cases are added.
Sponsors who fund this work, rather than run it, tend to ask the same handful of questions. Here is how we answer them, in plain terms.
Because point-to-point interfaces multiply and break, consuming effort while never making the estate genuinely interoperable. A standards-based FHIR foundation replaces that fragility with dependable, reusable exchange.
By governing quality, privacy and consent from the start. Interoperable data must also be trustworthy and handled appropriately, which is non-negotiable in this domain and built into how we design it.
Governed, interoperable data enables clinical, operational and research analytics that siloed, inconsistent data makes impractical. Connecting systems is the means; better care and insight are the end.
Because interfaces multiply and break, while a standards-based FHIR foundation gives dependable, reusable exchange. It replaces a growing maintenance burden with durable infrastructure.
By governing quality, privacy and consent from the start, so interoperable data is also trustworthy and appropriately used, which is non-negotiable in healthcare.
Governed, interoperable data enables clinical, operational and research analytics that siloed data makes impractical, which is where better care and insight come from.
By delivering incrementally alongside the systems clinicians already use, rather than through a disruptive replacement. The interoperability layer is added and proven on a contained scope first, so clinical operations continue uninterrupted while the foundation is built beneath them.
Whatever the engagement, you are left with tangible artifacts rather than a set of recommendations to implement yourself. The deliverables below are working outputs your teams can use and extend, not a slide deck that gathers dust.
Each is designed to be durable: documented, owned and operational, so the value of the engagement outlives it and the capability keeps running once we step back.
A standards-based FHIR interoperability strategy that replaces brittle point-to-point links.
Health data modelled to FHIR so clinical and analytical consumers share a common structure.
Pipelines that move and transform health data dependably between systems and into analytics.
Quality, privacy and consent controls, and governed data prepared for clinical and research analytics.
A short glossary for sponsors and stakeholders who fund this work without needing to live in the detail.
A widely adopted standard for exchanging health data, which replaces brittle custom interfaces with dependable, reusable connectivity.
The ability of different health systems to share and use data together, rather than each holding it in a silo.
Managing what patient data may be used for and by whom, an essential part of using health data appropriately.
A record of where health data came from and how it moved, supporting both trust and appropriate use.
Our guides, board papers and outlooks sit alongside this practice, drawing on the same integrated capability.
Yes. FHIR/HL7-based interoperability is central to our healthcare data work.
We design privacy in from the start, so interoperability and privacy reinforce each other and analytics stays within appropriate controls.
Yes - governed, privacy-aware foundations that enable analytics and research without compromising clinical integrity.
No. A FHIR-based interoperability layer sits alongside the systems you keep, giving them a common, standards-based way to exchange data. You gain dependable connectivity and governed, reusable data without a disruptive replacement of the applications clinicians already use.
By replacing a growing web of brittle point-to-point interfaces with a reusable standard. Each new bespoke interface adds fragility and maintenance; a FHIR foundation lets new consumers connect to a common structure, so connectivity becomes durable infrastructure rather than a perpetual integration project.
Yes. Most organisations begin with a priority set of systems or a specific clinical or analytical use case, prove the standards-based approach and the governance around it, and then extend the same foundation across further systems and uses from there.
As first-class parts of the design. Classification, access control and consent handling are built in, so interoperable data is also appropriately used. In healthcare this is non-negotiable, and it is why we treat governance as inseparable from interoperability rather than a later add-on.
Data engineers who build governed, standards-based foundations rather than sell a platform. That means the interoperability rests on real FHIR modelling, reliable pipelines and governance tailored to your estate, and it integrates with the systems you already run rather than assuming a single vendor's stack.
By preparing governed, interoperable data that clinical, operational and research analytics can actually use. Siloed, inconsistent data makes much of this impractical; a common, trustworthy foundation is what turns it into something teams can build on.
A focused first phase, typically a priority set of systems or a specific use case, is measured in weeks rather than years, because we prove the standards-based approach on a contained scope before extending it. You see a connected, governed result early, which is what justifies funding the next phase.
Yes. Standardising on FHIR aligns naturally with the direction of health-data interoperability requirements in most jurisdictions, and we tailor the modelling, privacy and consent handling to the specific regime you operate under, so compliance and capability advance together.
HIPAA, GDPR and regional health-data rules, with the control documentation and lineage that audits require.
Yes. We design standards-based integration across EHR, claims and ancillary systems to unify data for analytics.
We build quality, lineage and consistent coding into the governed foundation, so downstream analytics can be trusted.
Scope an engagement with a senior practitioner.
Enter your details and we will email the brochure download link to your inbox.
If the address is valid, the brochure download link is on its way. It can take a minute to arrive.